Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Role of Direct Immunofluorescence in Vasculitis: Challenging Dogma and Avoiding Pitfalls

Description

This presentation discusses the role of direct immunofluorescence (DIF) in diagnosing vasculitis, addressing its benefits, logistical considerations, and potential pitfalls. DIF is valuable for confirming diagnoses, especially in conditions like IgA vasculitis and hypocomplementemic urticarial vasculitis, where specific patterns can help distinguish various disease entities. The speaker highlights the significance of selecting appropriate lesions for biopsy, preferably early, intact, and non-ulcerated, to optimize DIF results. While discussing test sensitivity, he notes that DIF may occasionally outperform histopathology in early lesions, though it is crucial to recognize its limitations as not all granulocyte deposits indicate vasculitis. The benefits of retaining a comprehensive panel of conjugates for testing are emphasized, particularly to avoid missing significant conditions like cryoglobulinemia or ANCA-associated vasculitis. Potential pitfalls include interpreting non-vasculitis conditions as vasculitis and the risk of confusing various dermatoses due to overlapping clinical features. The speaker encourages careful examination and collaboration between clinicians and dermatopathologists to avoid misdiagnosis and improve diagnostic accuracy in vasculitis.

View more

Conclusions

  • Direct immunofluorescence (DIF) testing is an effective tool for diagnostic confirmation in vasculitis, particularly for IgA vasculitis.
  • DIF can help in predicting renal disease and guide clinical follow-up.
  • It is most effective when performed on lesional skin, ideally within 24-48 hours of lesion onset.
  • Limited panel DIF testing may compromise diagnostic accuracy and sensitivity for various types of vasculitis.
  • Triaging DIF testing based on histological findings may carry risks of misdiagnosis.
  • The sensitivity of DIF for vasculitis is around 75%, but specific results can vary depending on the clinical scenario.
  • Presence of IgA on DIF may indicate increased renal involvement in patients diagnosed with vasculitis.
  • There are clinical mimics of vasculitis that can lead to misinterpretation of DIF results.
  • Pitfalls in using DIF include confusion with non-specific deposits and overlooking subtle changes in histopathology.
  • Jennette et al., 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthr Rheumat 2013.
  • Sunderkotter et al. Nomenclature of cutaneous vasculitis. Arthr Rheumatol 2018; 70(2): 171-184.
  • Sanchez, N.P., et al., J Am Acad Dermatol, 1982. 7(5): p. 599-605.
  • Dincy, C.V., et al., J Eur Acad Dermatol Venereol, 2008. 22(7): p. 789-94.
  • Mehregan, D.R., M.J. Hall, and L.E. Gibson. J Am Acad Dermatol, 1992. 26(3 Pt 2): p. 441-8.
  • Davis, M.D., et al. J Am Acad Dermatol, 1998. 38(6 Pt 1): p. 899-905.
  • Takatu, C.M., et al., Clinicopathologic correlation of 282 leukocytoclastic vasculitis cases in a tertiary hospital: a focus on direct immunofluorescence findings at the blood vessel wall. Immunol Res, 2017. 65(1): p. 395-401.
  • Bauzá, A., A. España, and M. Idoate, Br J Dermatol, 2002. 146(4): p. 694-9.
  • Diaz-Perez, J.L., A.L. Schroeter, and R.K. Winkelmann, Arch Dermatol, 1980. 116(1): p. 56-8.
  • Sarkar, N., et al., Cureus, 2022. 14(5): p. e24845.
  • Byun, J.W., et al., Am J Dermatopathol, 2012. 34(2): p. 139-44.
  • Sais et al., Prognostic factors in leukocytoclastic vasculitis. Arch Dermatol 1998; 134: 309-315.
  • Reimann et al. Assessment of the cutaneous direct immunofluorescence assay. JAMA Dermatol 2021; 157(11): 1343-1348.
  • Lehman et al. Perspectives on the cutaneous direct immunofluorescence assay. JAMA Dermatol 2022; 158(6): 704-705.